SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ind Swift Laboratories gets TGA approval from Australia for seven APIs

27 Sep 2011 Evaluate

Ind Swift Laboratories (ISLL), a global pharmaceutical company, has got Therapeutic Goods Administration (TGA) approval from Australia for seven of its APIs - Donepezil HCI, Clarithromycin, Letrozole, Pioglitazone HCI, Ropinirole, Acamprosate and Aripiprazole to be manufactured at its facility at Derabassi. Australia is the most attractive market for pharmaceutical investment in the Asia Pacific region which is primarily due to its growing and ageing population, excellent access to medicines, and fast-recovering economy.

Australia's generics market will be worth $830 million this year, (Australian pharmaceutical market valued around $9 billion) and is expected to grow an average 7% a year, presenting 'huge opportunities' for manufacturers through tapping into the diabetes, oncology, neurological and cardiovascular disease markets.

The company has so far filed 374 DMFs with various regulatory authorities including 05 DMFs filed in Australia. Ind-Swift Laboratories is a part of the Ind-swift Group and is based at Chandigarh, India. The company is engaged in manufacturing of Active Pharmaceutical Ingredients (API). 

Ind-Swift Lab. Share Price

138.45 0.45 (0.33%)
11-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1279.70
Cipla 1304.70
Zydus Lifesciences 956.65
Lupin 2245.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×